ATAI | Atai Life Sciences N.V. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.3900 - 1.5500
52 Week Range	1.0300 - 2.5650
Beta	1.37
Implied Volatility	206.79%
IV Rank	36.47%
Day's Volume	1,901,958
Average Volume	2,830,652
Shares Outstanding	199,795,000
Market Cap	299,692,500
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-06-18

Valuation
Profitability
Growth
Health
P/E Ratio	-1.61
Forward P/E Ratio	-2.01
EPS	-0.93
1YR Price Target	11.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	83
Country	Germany
Website	ATAI

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

ATAI's peers: MNMD, SEEL, GHRS, FRLN, CYBN, FBIO, BPTH, VCNX, ELYM, OPT, MOLN, EWTX, ITOS, WSNAF, BVAXF, AGNPF, AXIM

*Chart delayed

Analyzing fundamentals for ATAI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ATAI Fundamentals page.

Watching at ATAI technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on ATAI Technicals page.